Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy.
作者信息
Benfaremo Devis, Perini Lucia, Marconi Valentina, Luchetti Michele Maria, Gabrielli Armando
机构信息
Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Clinica Medica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
出版信息
Eur J Intern Med. 2021 Jan;83:90-92. doi: 10.1016/j.ejim.2020.10.010. Epub 2020 Oct 15.
Abstract
摘要
相似文献
1
Disease course in patients with systemic autoimmune diseases: insights on the safety of immunosuppression during the SARS-CoV-2 outbreak in Italy.
Eur J Intern Med. 2021 Jan;83:90-92. doi: 10.1016/j.ejim.2020.10.010. Epub 2020 Oct 15.
2
SARS-CoV-2 infection among patients with systemic autoimmune diseases.
Autoimmun Rev. 2020 Jul;19(7):102575. doi: 10.1016/j.autrev.2020.102575. Epub 2020 May 5.
3
Cutaneous autoimmune diseases during COVID-19 pandemic.
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e667-e670. doi: 10.1111/jdv.16753. Epub 2020 Jul 2.
4
SARS CoV-2 infection among patients using immunomodulatory therapies.
Ann Rheum Dis. 2021 Feb;80(2):269-271. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.
5
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
6
COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.
J Am Acad Dermatol. 2021 Feb;84(2):563-568. doi: 10.1016/j.jaad.2020.08.012. Epub 2020 Aug 8.
7
Change over time of COVID-19 hospital presentation in Northern Italy.
Eur J Intern Med. 2020 Nov;81:100-103. doi: 10.1016/j.ejim.2020.09.021. Epub 2020 Sep 25.
8
After the COVID 19 outbreak in Italy: What have we learnt?
Travel Med Infect Dis. 2020 Nov-Dec;38:101761. doi: 10.1016/j.tmaid.2020.101761. Epub 2020 Jun 1.
9
Biologics in systemic autoimmune diseases during COVID-19 pandemic.
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
10
COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome.
Acta Haematol. 2020;143(6):574-582. doi: 10.1159/000510769. Epub 2020 Sep 15.
本文引用的文献
1
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
Arthritis Rheumatol. 2020 Oct;72(10):1600-1606. doi: 10.1002/art.41388. Epub 2020 Sep 6.
2
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.
Ann Rheum Dis. 2020 Jul;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877. Epub 2020 Jun 5.
3
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Ann Rheum Dis. 2020 Jul;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903. Epub 2020 May 28.
4
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.
Joint Bone Spine. 2020 Oct;87(5):439-443. doi: 10.1016/j.jbspin.2020.05.003. Epub 2020 May 20.
5
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
6
Biologics in Inflammatory Immune-mediated Systemic Diseases.
Curr Pharm Biotechnol. 2017;18(12):1008-1016. doi: 10.2174/1389201019666171226152448.
7
Biologics in Inflammatory and Immunomediated Arthritis.
Curr Pharm Biotechnol. 2017;18(12):989-1007. doi: 10.2174/1389201019666171226151852.
Zotero 插件